Market Overview

Amicus Extending Rally On Upgrades

Share:
Related FOLD
Amicus Therapeutics Gets European Commission Approval For Galafold in Patients With Fabry Disease
Today's Top 10 Pre-Market Gainers

Amicus Therapeutics (NASDAQ: FOLD) shares are up 12 percent Tuesday following a nine percent jump Monday.

This move comes after JP Morgan, Janney and Leerink Partners upgraded Amicus to buy Monday and Tuesday and significantly boosted their price targets. The median price target is $5.50, or 45.1 percent of additional upside (65 percent before the stocks started moving higher).

Leerink thinks that the Phase 3 study has a high chance for success: 75 percent in Europe and 50 percent in the United States. This compares to a 20 percent success rate previously.

Related: Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly

Leerink also expects top line results from study 012 at the end of July or beginning of August.

Shares of Amicus Were last trading up 12.5 percent in Tuesday’s pre-market session to $3.76. Shares have risen more than 42 percent in value year-to-date.

Latest Ratings for FOLD

DateFirmActionFromTo
May 2016Bank of AmericaInitiates Coverage onBuy
Apr 2016BairdInitiates Coverage onNeutral
Mar 2016Goldman SachsInitiates Coverage onNeutral

View More Analyst Ratings for FOLD
View the Latest Analyst Ratings

Posted-In: Janney JP Morgan LeerinkUpgrades Price Target Movers & Shakers Analyst Ratings General

 

Related Articles (FOLD)

View Comments and Join the Discussion!